Voyager Therapeutics (VYGR) News Today $5.45 -0.16 (-2.85%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$5.45 0.00 (0.00%) As of 01/31/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment RelevanceJanuary 30 at 5:43 PM | seekingalpha.comReviewing Kyverna Therapeutics (NASDAQ:KYTX) & Voyager Therapeutics (NASDAQ:VYGR)January 29 at 3:15 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Voyager Therapeutics (NASDAQ:VYGR)January 28, 2025 | americanbankingnews.comPositive Outlook for Voyager Therapeutics Driven by Promising CNS Gene Therapies and Innovative TRACER PlatformJanuary 27, 2025 | markets.businessinsider.comVoyager Therapeutics (NASDAQ:VYGR) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday.January 27, 2025 | marketbeat.comQ1 Earnings Estimate for VYGR Issued By Leerink PartnrsJanuary 26, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Forecast for VYGR Q1 Earnings?Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo expects that the compaJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Forecasts VYGR FY2025 EarningsJanuary 23, 2025 | americanbankingnews.comEquities Analysts Issue Forecasts for VYGR FY2025 EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Voyager Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($2.20) perJanuary 22, 2025 | marketbeat.comInsider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells 3,087 Shares of StockJanuary 16, 2025 | insidertrades.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $15,712.83 in StockVoyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) COO Robin Swartz sold 3,087 shares of the stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $5.09, for a total value of $15,712.83. Following the sale, the chief operating officer now owns 109,241 shares of the company's stock, valued at $556,036.69. This represents a 2.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.January 15, 2025 | marketbeat.comOppenheimer Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)January 15, 2025 | markets.businessinsider.comCantor Fitzgerald Weighs in on VYGR FY2024 EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Voyager Therapeutics in a note issued to investors on Monday, January 13th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company wiJanuary 14, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Voyager Therapeutics (VYGR) with Overweight RecommendationJanuary 11, 2025 | msn.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of "Buy" by BrokeragesShares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have earned a consensus rating of "Buy" from the nine brokerages that are presently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the coJanuary 11, 2025 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor FitzgeraldCantor Fitzgerald assumed coverage on Voyager Therapeutics in a research report on Friday. They issued an "overweight" rating for the company.January 10, 2025 | marketbeat.comJane Street Group LLC Lowers Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)Jane Street Group LLC trimmed its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 56.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 84,652 shares of the company's stock after selling 108,141 shares during the period. JaneJanuary 6, 2025 | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by State Street CorpState Street Corp trimmed its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 50.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 892,743 shares of the company's stock after selling 896,446 shares duDecember 30, 2024 | marketbeat.comVoyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | msn.comVoyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.comInsider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells 6,500 Shares of StockDecember 27, 2024 | insidertrades.comRobin Swartz Sells 6,500 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) StockVoyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) COO Robin Swartz sold 6,500 shares of the business's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 26, 2024 | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of "Buy" by AnalystsShares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are currently covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendatioDecember 17, 2024 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Downgraded by StockNews.com to HoldStockNews.com downgraded Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday.December 13, 2024 | marketbeat.comErste Asset Management GmbH Acquires New Shares in Voyager Therapeutics, Inc. (NASDAQ:VYGR)Erste Asset Management GmbH bought a new stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,058,378 shares of the company's stock, valued atDecember 3, 2024 | marketbeat.comVoyager Therapeutics initiated with a Buy at CitiDecember 3, 2024 | markets.businessinsider.comA Glimpse Into The Expert Outlook On Voyager Therapeutics Through 5 AnalystsDecember 2, 2024 | benzinga.comCitigroup Initiates Coverage of Voyager Therapeutics (VYGR) with Buy RecommendationDecember 2, 2024 | msn.comWedbush upgrades Voyager to Outperform on pipeline progressNovember 29, 2024 | markets.businessinsider.comVoyager Therapeutics (NASDAQ:VYGR) Earns Outperform Rating from Analysts at WedbushWedbush assumed coverage on Voyager Therapeutics in a research note on Friday. They issued an "outperform" rating and a $11.00 price objective for the company.November 29, 2024 | marketbeat.comVestal Point Capital LP Sells 110,000 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)Vestal Point Capital LP cut its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 18.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 490,000 shares of the company's stock after selling 110,000 sharNovember 29, 2024 | marketbeat.comGreat Point Partners LLC Sells 641,574 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)Great Point Partners LLC reduced its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 40.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 959,953 shares of the coNovember 27, 2024 | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of "Buy" by BrokeragesShares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assignedNovember 22, 2024 | marketbeat.comVoyager Therapeutics selects VY1706 for program in Alzheimer’s DiseaseNovember 21, 2024 | markets.businessinsider.comVoyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s DiseaseNovember 20, 2024 | finance.yahoo.comVoyager Therapeutics' TRACER Platform Targets CNS Market: Here's Why I'm NeutralNovember 18, 2024 | seekingalpha.comStockNews.com Upgrades Voyager Therapeutics (NASDAQ:VYGR) to "Buy"StockNews.com raised shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Monday.November 18, 2024 | marketbeat.comHC Wainwright Has Bullish Forecast for VYGR FY2024 EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for shares of Voyager Therapeutics in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will pNovember 18, 2024 | marketbeat.comLeerink Partnrs Has Negative Outlook of VYGR FY2024 EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Leerink Partnrs lowered their FY2024 earnings per share estimates for shares of Voyager Therapeutics in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will earn ($0.66) pNovember 15, 2024 | marketbeat.comDeclining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)?November 15, 2024 | finance.yahoo.comWe've been wrong about Uranus for nearly 40 years, new analysis of Voyager 2 data revealsNovember 14, 2024 | msn.comCSPD orders shelter in place around N. Academy and VoyagerNovember 14, 2024 | msn.comVoyager Therapeutics: Promising Alzheimer’s Program and Strong Financial Position Support Buy RatingNovember 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Voyager Therapeutics (VYGR), BioNTech SE (BNTX)November 14, 2024 | markets.businessinsider.comVoyager Therapeutics' (VYGR) Buy Rating Reiterated at Canaccord Genuity GroupCanaccord Genuity Group reiterated a "buy" rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday.November 14, 2024 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday.November 14, 2024 | marketbeat.comVoyager Therapeutics, Inc.: Voyager Reports Third Quarter 2024 Financial and Operating ResultsNovember 13, 2024 | finanznachrichten.deVoyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...November 13, 2024 | uk.finance.yahoo.comVoyager Therapeutics: Solid Financial Foundation and Strategic Progress Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comVoyager Therapeutics Reports Strong Q3 2024 ProgressNovember 13, 2024 | markets.businessinsider.com Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Media Mentions By Week VYGR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYGR News Sentiment▼0.670.69▲Average Medical News Sentiment VYGR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYGR Articles This Week▼95▲VYGR Articles Average Week Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcus Biosciences News Syndax Pharmaceuticals News Calliditas Therapeutics AB (publ) News Aurinia Pharmaceuticals News Adaptive Biotechnologies News Collegium Pharmaceutical News Intellia Therapeutics News Spyre Therapeutics News Gyre Therapeutics News Enliven Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYGR) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
